Skip to content
Film Television Auditions – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
September 11, 2026
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
September 1, 2026
New Phase 3b data on Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
August 31, 2026
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
August 12, 2026
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
August 5, 2026
Lilly’s olomorasib receives U.S. FDA’s Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
August 3, 2026
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
July 22, 2026
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
July 16, 2026
/C O R R E C T I O N — Eli Lilly and Company/
July 9, 2026
1
2
3
…
6
Next Page
→